Kahl BS - Search Results

1

Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.

Oberley MJ, Rajguru SA, Zhang C, Kim K, Shaw GR, Grindle KM, Kahl BS, Kanugh C, Laffin J, Yang DT. Oberley MJ, et al. Among authors: kahl bs. Histopathology. 2013 Oct;63(4):499-508. doi: 10.1111/his.12207. Epub 2013 Aug 8. Histopathology. 2013. PMID: 23926923 Free PMC article.

2

Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.

Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J, Jumonville A. Kahl BS, et al. Cancer Invest. 2005;23(1):13-8. Cancer Invest. 2005. PMID: 15779863 Clinical Trial.

3

Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.

Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH; Wisconsin Oncology Network. Kahl BS, et al. Ann Oncol. 2006 Sep;17(9):1418-23. doi: 10.1093/annonc/mdl127. Epub 2006 Jun 9. Ann Oncol. 2006. PMID: 16766582 Free article. Clinical Trial.

4

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.

Petrich A, Kahl B, Bailey H, Kim K, Turman N, Juckett M. Petrich A, et al. Leuk Lymphoma. 2008 Jan;49(1):57-61. doi: 10.1080/10428190701713648. Leuk Lymphoma. 2008. PMID: 18203012 Free PMC article. Clinical Trial.

5

Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.

Kahl B. Kahl B. Semin Hematol. 2008 Apr;45(2):90-4. doi: 10.1053/j.seminhematol.2008.02.003. Semin Hematol. 2008. PMID: 18381103 Free PMC article. Review.

6

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.

Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Yang DT, et al. Among authors: kahl bs. Mol Cancer. 2008 May 19;7:40. doi: 10.1186/1476-4598-7-40. Mol Cancer. 2008. PMID: 18489772 Free PMC article.

7

Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.

Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS. Chang JE, et al. Among authors: kahl bs. Hematol Oncol. 2009 Mar;27(1):11-6. doi: 10.1002/hon.870. Hematol Oncol. 2009. PMID: 18668698 Free PMC article. Clinical Trial.

8

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S. Markovina S, et al. Among authors: kahl bs. Mol Cancer Res. 2008 Aug;6(8):1356-64. doi: 10.1158/1541-7786.MCR-08-0108. Mol Cancer Res. 2008. PMID: 18708367 Free PMC article.

9

Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia.

Chang JE, Medlin SC, Kahl BS, Longo WL, Williams EC, Lionberger J, Kim K, Kim J, Esterberg E, Juckett MB. Chang JE, et al. Among authors: kahl bs. Leuk Lymphoma. 2008 Dec;49(12):2298-307. doi: 10.1080/10428190802517732. Leuk Lymphoma. 2008. PMID: 19052977 Free PMC article. Clinical Trial.

10

Marginal zone lymphomas: management of nodal, splenic, and MALT NHL.

Kahl B, Yang D. Kahl B, et al. Hematology Am Soc Hematol Educ Program. 2008:359-64. doi: 10.1182/asheducation-2008.1.359. Hematology Am Soc Hematol Educ Program. 2008. PMID: 19074110

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

284 results

Search Page

Filters